Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients: a meta-analysis.
Clozapine
Drug interaction
Meta-analysis
Pharmacokinetic
Propranolol
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
received:
25
01
2024
accepted:
09
04
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
aheadofprint
Résumé
Clozapine is the effective therapy for treatment-refractory schizophrenia. However, the use of clozapine is limited by its adverse effects. As propranolol is frequently used for the prevention and treatment of clozapine-induced tachycardia, we performed a meta-analysis to evaluate the effects of propranolol on steady state pharmacokinetics of clozapine in schizophrenic patients. We included 16 retrospective studies on the effects of propranolol on steady state pharmacokinetics of clozapine in schizophrenic patients, with data from both generic and brand name treatment phases in eight clozapine bioequivalence studies conducted in a single center in China from 2018 to 2022. Review Manager 5.4 was used for meta-analysis of the included studies. The SMDs with 95% CIs of AUC The combination with propranolol could significantly increase systemic exposure and extended T
Identifiants
pubmed: 38639762
doi: 10.1007/s00228-024-03690-w
pii: 10.1007/s00228-024-03690-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Barnes TR, Drake R, Paton C (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology 34(1):3–78
Dettling M, Sachse C, Brockmöller J, Schley J, Müller-Oerlinghausen B, Pickersgill I, Rolfs A, Schaub RT, Schmider J (2000) Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 152(1):80–86
doi: 10.1007/s002130000503
pubmed: 11041319
Khokhar JY, Henricks AM, Sullivan EDK, Green AI (2018) unique effects of clozapine: a pharmacological perspective. Advances in pharmacology (San Diego, Calif) 82:137–162
pubmed: 29413518
Mustafa FA (2013) Schizophrenia past clozapine: what works? J Clin Psychopharmacol 33(1):63–68
doi: 10.1097/JCP.0b013e31827a813b
pubmed: 23277242
Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B (2009) Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol 32(5):290–292
doi: 10.1097/WNF.0b013e3181a620b2
pubmed: 19820431
van Dam D, Bosch TM, Mookhoek EJ, Hovens JE (2012) Treatment of clozapine-induced tachycardia with propranolol complicated by psoriasis. Tijdschr Psychiatr 54(3):285–289
pubmed: 22422422
Brennan D, Lal S, Hugo F, Waters F (2024) Clozapine-related tachycardia: a conundrum to identify and treat 32(1):84–88
Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers–N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39(4):421–431
doi: 10.1111/j.1365-2125.1995.tb04472.x
pubmed: 7640150
pmcid: 1365131
Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S (1994) Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug metabolism and disposition: the biological fate of chemicals 22(6):909–915
pubmed: 7895609
Tolledo EC, Miksys S (2020) Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses. Br J Pharmacol 177(3):701–712
doi: 10.1111/bph.14884
pubmed: 31648367
pmcid: 7012948
Chetty M, Murray M (2007) CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8(4):307–313
doi: 10.2174/138920007780655469
pubmed: 17504220
Fischer V, Vogels B, Maurer G, Tynes RE (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260(3):1355–1360
pubmed: 1545398
Stolz B, McCollum B (2015) Clozapine levels rise and fall with propranolol: A case report. J Pharm Pract 28:370
Yang X, Zhu R, Yan Q, Yang L, Li J, Fan X, Chen J, Wu H, Fang P (2021) Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients. Chinese Journal of Hospital Pharmacy 41(19):1950–1954
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1
doi: 10.1186/2046-4053-4-1
pubmed: 25554246
pmcid: 4320440
Yang X, Yan Q, Yang L, Li J, Fan X, Chen J, Wu H, Cai H, Zhu R, Fang P (2021) Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: a randomized, two-period, crossover study. Int J Clin Pharmacol Ther 59(8):578–584
doi: 10.5414/CP203864
pubmed: 34142950
Food And Drug Administration (2017) Drug development and drug interactions: table of substrates, Inhibitors and Inducers
Yuen JWY, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM (2018) Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci 12:203
doi: 10.3389/fnins.2018.00203
pubmed: 29670504
pmcid: 5893810
Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S (1981) Clozapine: plasma levels and prolactin response. Psychopharmacology 73(2):184–187
doi: 10.1007/BF00429215
pubmed: 6785813
Young CR, Bowers MB Jr, Mazure CM (1998) Management of the adverse effects of clozapine. Schizophr Bull 24(3):381–390
doi: 10.1093/oxfordjournals.schbul.a033333
pubmed: 9718630
Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M (2015) “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 48(1):11–14
pubmed: 25376977
Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11(5):289–301
doi: 10.1097/00131746-200509000-00003
pubmed: 16184070